https://www.leverventure.com/ 2026-10-11 weekly 1.0 https://www.leverventure.com/about 2026-10-11 monthly 0.9 https://www.leverventure.com/thesis 2026-10-11 monthly 0.9 https://www.leverventure.com/leversolutions 2026-10-11 monthly 0.9 https://www.leverventure.com/apply 2026-10-11 monthly 0.8 https://www.leverventure.com/research 2026-10-11 monthly 0.8 https://www.leverventure.com/team 2026-10-11 monthly 0.8 https://www.leverventure.com/team/peleg-chevion 2026-10-11 monthly 0.8 https://www.leverventure.com/team/jose-vasquez 2026-10-11 monthly 0.8 https://www.leverventure.com/insights 2026-10-11 daily 0.9 https://www.leverventure.com/contact 2026-10-11 monthly 0.7 https://www.leverventure.com/privacy-policy 2026-10-11 yearly 0.3 https://www.leverventure.com/leverventure-terms-and-conditions-of-use 2026-10-11 yearly 0.3 https://www.leverventure.com/disclaimer 2026-10-11 yearly 0.3 https://www.leverventure.com/insights/growth-equity 2026-10-11 weekly 0.8 https://www.leverventure.com/insights/life-sciences 2026-10-11 weekly 0.8 https://www.leverventure.com/insights/ai 2026-10-11 weekly 0.8 https://www.leverventure.com/insights/impact 2026-10-11 weekly 0.8 https://www.leverventure.com/learn 2026-10-11 monthly 0.9 https://www.leverventure.com/learn/ldt-clia 2026-10-11 monthly 0.8 https://www.leverventure.com/learn/moic 2026-10-11 monthly 0.8 https://www.leverventure.com/learn/carried-interest 2026-10-11 monthly 0.8 https://www.leverventure.com/learn/secondaries 2026-10-11 monthly 0.8 https://www.leverventure.com/learn/ai-diligence 2026-10-11 monthly 0.8 https://www.leverventure.com/learn/spv 2026-10-11 monthly 0.8 https://www.leverventure.com/learn/tvpi 2026-10-11 monthly 0.8 https://www.leverventure.com/learn/mso 2026-10-11 monthly 0.8 https://www.leverventure.com/learn/growth-equity 2026-10-11 monthly 0.8 https://www.leverventure.com/learn/dpi 2026-10-11 monthly 0.8 https://www.leverventure.com/learn/capital-call 2026-10-11 monthly 0.8 https://www.leverventure.com/learn/ddq 2026-10-11 monthly 0.8 https://www.leverventure.com/learn/family-office-pe 2026-10-11 monthly 0.8 https://www.leverventure.com/learn/samd 2026-10-11 monthly 0.8 https://www.leverventure.com/learn/mid-market 2026-10-11 monthly 0.8 https://www.leverventure.com/learn/j-curve 2026-10-11 monthly 0.8 https://www.leverventure.com/learn/operating-partner 2026-10-11 monthly 0.8 https://www.leverventure.com/learn/distribution-waterfall 2026-10-11 monthly 0.8 https://www.leverventure.com/learn/illiquidity-premium 2026-10-11 monthly 0.8 https://www.leverventure.com/learn/co-investment 2026-10-11 monthly 0.8 https://www.leverventure.com/learn/key-person 2026-10-11 monthly 0.8 https://www.leverventure.com/learn/emerging-manager 2026-10-11 monthly 0.8 https://www.leverventure.com/thesis/biopharma-therapeutics 2026-10-11 monthly 0.9 https://www.leverventure.com/thesis/diagnostics-precision-medicine 2026-10-11 monthly 0.9 https://www.leverventure.com/thesis/devices-robotics 2026-10-11 monthly 0.9 https://www.leverventure.com/thesis/digital-health-delivery 2026-10-11 monthly 0.9 https://www.leverventure.com/thesis/longevity-neuro 2026-10-11 monthly 0.9 https://www.leverventure.com/thesis/growth-equity 2026-10-11 monthly 0.9 https://www.leverventure.com/thesis/healthcare-growth-equity 2026-10-11 monthly 0.9 https://www.leverventure.com/thesis/ai-as-accelerant 2026-10-11 monthly 0.9 https://www.leverventure.com/insights/life-sciences/the-investment-thesis-you-can-be-held-to 2026-10-02 monthly 0.7 https://www.leverventure.com/assets/site/9c5d43f7b870.jpg The Investment Thesis You Can Be Held To https://www.leverventure.com/insights/life-sciences/medtech-surgical-robotics-growth-capital-guide 2026-09-22 monthly 0.7 https://www.leverventure.com/og/insights/life-sciences/medtech-surgical-robotics-growth-capital-guide.png How Medtech and Surgical Robotics Founders Should Approach Growth Capital https://www.leverventure.com/insights/growth-equity/growth-equity-life-sciences-market-study-2026 2026-09-17 monthly 0.7 https://www.leverventure.com/og/insights/growth-equity/growth-equity-life-sciences-market-study-2026.png Growth Equity in Life Sciences: 2026 Market Study https://www.leverventure.com/insights/growth-equity/operational-due-diligence-the-gp-checklist 2026-09-16 monthly 0.7 https://www.leverventure.com/assets/site/873276dcde4a.jpg Operational Due Diligence: The GP Checklist Nobody Publishes https://www.leverventure.com/insights/life-sciences/longevity-neuro-founder-growth-capital-guide 2026-09-15 monthly 0.7 https://www.leverventure.com/og/insights/life-sciences/longevity-neuro-founder-growth-capital-guide.png Funding the Longevity Economy: A Growth Capital Guide for Longevity and Neuro Founders https://www.leverventure.com/insights/growth-equity/private-equity-meets-the-mid-market 2026-09-13 monthly 0.7 https://www.leverventure.com/og/insights/growth-equity/private-equity-meets-the-mid-market.png Private Equity Meets the Mid-Market: Borrowing PE's Discipline Without the Buyout https://www.leverventure.com/insights/growth-equity/the-operating-record 2026-09-02 monthly 0.7 https://www.leverventure.com/assets/site/5e3322e1386d.jpg The Operating Record: What It Supports and What It Does Not https://www.leverventure.com/insights/growth-equity/family-office-guide-emerging-growth-equity-managers 2026-09-15 monthly 0.7 https://www.leverventure.com/og/insights/growth-equity/family-office-guide-emerging-growth-equity-managers.png Family Office Guide to Emerging Growth Equity Managers https://www.leverventure.com/insights/ai/ai-diligence-eleven-questions 2026-08-27 monthly 0.7 https://www.leverventure.com/assets/site/e59aa4061ad7.jpg AI Diligence: Eleven Questions, and What the Regulatory Record Answers https://www.leverventure.com/insights/growth-equity/term-sheet-guide-life-sciences-healthcare-founders 2026-09-15 monthly 0.7 https://www.leverventure.com/og/insights/growth-equity/term-sheet-guide-life-sciences-healthcare-founders.png The Term Sheet Guide for Life Sciences and Healthcare Founders https://www.leverventure.com/insights/growth-equity/the-state-of-venture-capital 2026-09-13 monthly 0.7 https://www.leverventure.com/og/insights/growth-equity/the-state-of-venture-capital.png The State of Venture Capital: How the Power Law Broke the Middle — and What Comes Next https://www.leverventure.com/insights/growth-equity/first-time-fund-back-office 2026-08-13 monthly 0.7 https://www.leverventure.com/assets/site/0f1c99e56eaf.jpg What a First-Time Fund's Back Office Actually Looks Like https://www.leverventure.com/insights/growth-equity/operator-led-vs-financial-sponsor-growth-equity 2026-09-15 monthly 0.7 https://www.leverventure.com/og/insights/growth-equity/operator-led-vs-financial-sponsor-growth-equity.png Operator-Led vs. Financial-Sponsor Growth Equity: What an Operating Partner Changes for LPs https://www.leverventure.com/insights/growth-equity/the-finance-of-scaling 2026-09-13 monthly 0.7 https://www.leverventure.com/og/insights/growth-equity/the-finance-of-scaling.png The Finance of Scaling: A Growth-Stage Operator's Guide to the Metrics That Move Enterprise Value https://www.leverventure.com/insights/ai/digital-transformation-as-an-investment-thesis 2026-09-13 monthly 0.7 https://www.leverventure.com/og/insights/ai/digital-transformation-as-an-investment-thesis.png Digital Transformation as an Investment Thesis: Why Most Programs Fail and How Operator-Led Capital Fixes Them https://www.leverventure.com/insights/growth-equity/j-curve-is-different-in-life-sciences 2026-07-14 monthly 0.7 https://www.leverventure.com/assets/site/b625a6dfd3d1.jpg The J-Curve Is Different in Life Sciences, and Allocators Should Price It https://www.leverventure.com/insights/life-sciences/operational-infrastructure-fundraising-growth-stage-founders 2026-09-13 monthly 0.7 https://www.leverventure.com/og/insights/life-sciences/operational-infrastructure-fundraising-growth-stage-founders.png When Your Operational Infrastructure Is the Fundraising Story: What Growth-Stage Founders Actually Get Scrutinized On https://www.leverventure.com/insights/growth-equity/dpi-is-the-only-number 2026-06-23 monthly 0.7 https://www.leverventure.com/assets/site/195ebe7d62af.jpg DPI Is the Only Number an Allocator Should Trust Right Now https://www.leverventure.com/insights/life-sciences/ai-infrastructure-life-sciences-healthcare-founders 2026-09-13 monthly 0.7 https://www.leverventure.com/og/insights/life-sciences/ai-infrastructure-life-sciences-healthcare-founders.png AI Infrastructure for Life Sciences and Healthcare Founders: Where to Build, Where to Wait https://www.leverventure.com/insights/growth-equity/dual-use-deep-tech-defense-adjacent-growth-equity-playbook 2026-09-13 monthly 0.7 https://www.leverventure.com/og/insights/growth-equity/dual-use-deep-tech-defense-adjacent-growth-equity-playbook.png Dual-Use Deep Tech: The Defense-Adjacent Growth-Equity Playbook for Founders https://www.leverventure.com/insights/growth-equity/european-and-american-waterfalls 2026-06-09 monthly 0.7 https://www.leverventure.com/assets/site/0ca734aac0c9.jpg Carried Interest: European and American Waterfalls, Side by Side https://www.leverventure.com/insights/growth-equity/emerging-growth-equity-managers-founder-evaluation-guide-2025 2026-09-13 monthly 0.7 https://www.leverventure.com/og/insights/growth-equity/emerging-growth-equity-managers-founder-evaluation-guide-2025.png Emerging Growth Equity Managers: The Founder's Complete Evaluation Guide for 2025 https://www.leverventure.com/insights/growth-equity/best-growth-equity-firms-life-sciences 2026-10-11 monthly 0.7 https://www.leverventure.com/og/insights/growth-equity/best-growth-equity-firms-life-sciences.png Best Growth Equity Firms for Life Sciences in 2026: A Founder's Field Guide https://www.leverventure.com/insights/growth-equity/operating-partners-first-hundred-days 2026-05-19 monthly 0.7 https://www.leverventure.com/assets/site/de701f65197f.jpg The Operating Partner's First Hundred Days, With Owners and Dates https://www.leverventure.com/insights/growth-equity/key-person-gp-commitment-two-partner-firm 2026-05-05 monthly 0.7 https://www.leverventure.com/assets/site/5123f5daa97b.jpg Key Person, GP Commitment and Source of Funds in a Two-Partner Firm https://www.leverventure.com/insights/life-sciences/quality-of-earnings-with-no-earnings 2026-04-21 monthly 0.7 https://www.leverventure.com/assets/site/8beeb52e8bc9.jpg Quality of Earnings in a Company With No Earnings https://www.leverventure.com/insights/growth-equity/continuation-funds-from-the-gps-side 2026-04-07 monthly 0.7 https://www.leverventure.com/assets/site/a0a3555c16c6.jpg Continuation Funds, Read From the GP's Side https://www.leverventure.com/insights/growth-equity/spv-fund-or-co-invest 2026-03-24 monthly 0.7 https://www.leverventure.com/assets/site/dcf4ee263762.jpg SPV, Fund or Co-Invest: Choosing the Vehicle https://www.leverventure.com/insights/growth-equity/value-creation-without-control 2026-03-10 monthly 0.7 https://www.leverventure.com/assets/site/7c46b5a3ea76.jpg Value Creation in a Company You Do Not Control https://www.leverventure.com/insights/life-sciences/mid-market-healthcare-why-the-thesis-only-works-here 2026-02-24 monthly 0.7 https://www.leverventure.com/assets/site/1a213e8dcc3a.jpg Mid-Market Healthcare: Why the Thesis Only Works Here https://www.leverventure.com/insights/life-sciences/why-life-sciences-why-now 2026-02-10 monthly 0.7 https://www.leverventure.com/assets/site/c9620a6e6f9a.jpg Why Life Sciences, Why Now: The Thesis in Full https://www.leverventure.com/insights/ai/which-ai-healthcare-claims-survive 2026-01-27 monthly 0.7 https://www.leverventure.com/assets/site/b5f6a3555c5a.jpg Which AI Healthcare Claims Survive a Regulatory Record https://www.leverventure.com/insights/life-sciences/risk-adjusted-npv-and-why-every-other-method-breaks 2025-10-14 monthly 0.7 https://www.leverventure.com/assets/site/78436e056c2c.jpg Risk-Adjusted NPV, and Why Every Other Method Breaks on Clinical Risk https://www.leverventure.com/insights/life-sciences/diligence-checklist-for-a-life-sciences-growth-round 2025-09-30 monthly 0.7 https://www.leverventure.com/assets/site/16a7521c0e7e.jpg The Diligence Checklist for a Life-Sciences Growth Round https://www.leverventure.com/insights/growth-equity/vc-market-reset-growth-equity 2026-09-13 monthly 0.7 https://www.leverventure.com/og/insights/growth-equity/vc-market-reset-growth-equity.png VC Market Reset: Implications for Growth Equity Investors https://www.leverventure.com/insights/life-sciences/precedent-transactions-with-four-comparables 2025-08-28 monthly 0.7 https://www.leverventure.com/assets/site/f14f2b61dbf2.jpg Precedent Transactions When There Are Four Comparables https://www.leverventure.com/insights/growth-equity/secondary-markets-growth-equity 2026-09-13 monthly 0.7 https://www.leverventure.com/og/insights/growth-equity/secondary-markets-growth-equity.png Secondary Markets in Growth Equity: 2025 Liquidity Revolution https://www.leverventure.com/insights/growth-equity/saas-metrics-evolution-2024 2026-09-13 monthly 0.7 https://www.leverventure.com/og/insights/growth-equity/saas-metrics-evolution-2024.png SaaS Business Models: Evolution Beyond the Rule of 40 https://www.leverventure.com/insights/impact/roi-squared-investment-philosophy 2026-09-15 monthly 0.7 https://www.leverventure.com/og/insights/impact/roi-squared-investment-philosophy.png The ROI² Philosophy: Returns and Impact https://www.leverventure.com/insights/ai/quantum-computing-investment-thesis 2026-09-13 monthly 0.7 https://www.leverventure.com/og/insights/ai/quantum-computing-investment-thesis.png Quantum Computing Investment Thesis: Beyond the Hype to 2028 Reality https://www.leverventure.com/insights/life-sciences/precision-medicine-investment-landscape 2026-09-13 monthly 0.7 https://www.leverventure.com/og/insights/life-sciences/precision-medicine-investment-landscape.png Precision Medicine Investment Landscape 2025 https://www.leverventure.com/insights/growth-equity/co-investment-from-the-side-that-offers-it 2025-07-21 monthly 0.7 https://www.leverventure.com/assets/site/10b0c71ca687.jpg Co-Investment, From the Side That Offers It https://www.leverventure.com/insights/life-sciences/precision-medicine-cancer-treatment 2026-09-13 monthly 0.7 https://www.leverventure.com/og/insights/life-sciences/precision-medicine-cancer-treatment.png Precision Medicine Breakthroughs: Making Personalized Cancer Treatment Accessible https://www.leverventure.com/insights/growth-equity/platform-build-buy-strategy 2026-09-13 monthly 0.7 https://www.leverventure.com/og/insights/growth-equity/platform-build-buy-strategy.png Platform Company Build-and-Buy Strategy: Scaling Through M&A https://www.leverventure.com/insights/growth-equity/operating-partner-evolution 2026-09-13 monthly 0.7 https://www.leverventure.com/og/insights/growth-equity/operating-partner-evolution.png Operating Partner Evolution: Beyond Advisory to Value Creation https://www.leverventure.com/insights/growth-equity/middle-market-pe-sweet-spot 2026-09-13 monthly 0.7 https://www.leverventure.com/og/insights/growth-equity/middle-market-pe-sweet-spot.png Middle Market Private Equity: The Overlooked Sweet Spot https://www.leverventure.com/insights/life-sciences/mental-health-tech-market-opportunity 2026-09-13 monthly 0.7 https://www.leverventure.com/og/insights/life-sciences/mental-health-tech-market-opportunity.png Mental Health Tech: The $5.5B Market Opportunity https://www.leverventure.com/insights/life-sciences/mental-health-tech-access 2026-09-13 monthly 0.7 https://www.leverventure.com/og/insights/life-sciences/mental-health-tech-access.png Mental Health Technology: Breaking Down Treatment Access Barriers https://www.leverventure.com/insights/ai/generative-ai-enterprise-value 2026-09-13 monthly 0.7 https://www.leverventure.com/og/insights/ai/generative-ai-enterprise-value.png Generative AI: Separating Hype from Enterprise Value https://www.leverventure.com/insights/life-sciences/gene-therapy-commercial-viability 2026-09-13 monthly 0.7 https://www.leverventure.com/og/insights/life-sciences/gene-therapy-commercial-viability.png Gene Therapy Commercial Viability: From Approval to Patient Access https://www.leverventure.com/insights/life-sciences/fda-digital-health-guidance 2026-09-13 monthly 0.7 https://www.leverventure.com/og/insights/life-sciences/fda-digital-health-guidance.png FDA Digital Health Guidance: Regulatory Clarity Accelerates Innovation https://www.leverventure.com/insights/growth-equity/the-management-fee-and-what-it-pays-for 2025-04-29 monthly 0.7 https://www.leverventure.com/assets/site/1eaecc39b76c.jpg The Management Fee, and What It Actually Pays For https://www.leverventure.com/insights/impact/esg-integration-investment-diligence 2026-09-13 monthly 0.7 https://www.leverventure.com/og/insights/impact/esg-integration-investment-diligence.png ESG Integration in Investment Due Diligence https://www.leverventure.com/insights/growth-equity/fund-of-funds-and-why-an-emerging-manager-meets-one 2025-04-14 monthly 0.7 https://www.leverventure.com/assets/site/39eb94a8f8c3.jpg Fund of Funds, and Why an Emerging Manager Meets One https://www.leverventure.com/insights/growth-equity/hurdle-rate-defined-against-market-convention 2025-04-03 monthly 0.7 https://www.leverventure.com/assets/site/d71ba0778acb.jpg The Hurdle Rate, Defined Against Market Convention https://www.leverventure.com/insights/life-sciences/digital-health-ai-diagnostics 2026-09-13 monthly 0.7 https://www.leverventure.com/og/insights/life-sciences/digital-health-ai-diagnostics.png Digital Health: From Telemedicine to AI Diagnostics https://www.leverventure.com/insights/life-sciences/democratizing-healthcare-digital-platforms 2026-09-13 monthly 0.7 https://www.leverventure.com/og/insights/life-sciences/democratizing-healthcare-digital-platforms.png Democratizing Healthcare Access: Digital Platforms Bridging Rural Care Gaps https://www.leverventure.com/insights/growth-equity/cross-border-investment-complexity 2026-09-13 monthly 0.7 https://www.leverventure.com/og/insights/growth-equity/cross-border-investment-complexity.png Cross-Border Investment: Navigating Complexity for Returns https://www.leverventure.com/insights/growth-equity/carve-out-acquisitions-playbook 2026-09-13 monthly 0.7 https://www.leverventure.com/og/insights/growth-equity/carve-out-acquisitions-playbook.png Carve-Out Acquisitions: The Execution Playbook https://www.leverventure.com/insights/growth-equity/building-value-beyond-capital 2026-09-15 monthly 0.7 https://www.leverventure.com/og/insights/growth-equity/building-value-beyond-capital.png Building Value Beyond Capital: Our Force Multiplier Approach https://www.leverventure.com/insights/life-sciences/biotech-funding-post-ipo-window 2026-09-13 monthly 0.7 https://www.leverventure.com/og/insights/life-sciences/biotech-funding-post-ipo-window.png Biotech Funding Environment: Post-IPO Window Analysis https://www.leverventure.com/insights/impact/ather-energy-electric-mobility-case-study 2026-09-13 monthly 0.7 https://www.leverventure.com/og/insights/impact/ather-energy-electric-mobility-case-study.png Industry Case Study: Ather Energy's Electric Mobility Revolution https://www.leverventure.com/insights/ai/ai-implementation-framework 2026-09-13 monthly 0.7 https://www.leverventure.com/og/insights/ai/ai-implementation-framework.png AI Implementation Framework for Growth Companies https://www.leverventure.com/insights/growth-equity/growth-equity-firms-ai-healthcare-playbook 2026-09-15 monthly 0.7 https://www.leverventure.com/og/insights/growth-equity/growth-equity-firms-ai-healthcare-playbook.png Growth Equity Firms in AI Healthcare: The Operator's Playbook for Raising Growth Capital in 2025